India is often called the “Pharmacy of the World,” supplying affordable generic medicines to over 200 countries. But how does the country’s drug regulator ensure those medicines meet quality standards? The answer lies in the CDSCO’s ongoing surveillance system — and one of its most important tools is the NSQ (Not of Standard Quality) alert.
🔍 What Are NSQ Drug Alerts?
NSQ stands for “Not of Standard Quality.” When the Central Drugs Standard Control Organization (CDSCO) — India’s national drug regulator — tests medicine samples collected from markets, pharmacies, and manufacturing sites, any sample that fails to meet the prescribed standards is classified as NSQ. These alerts are published monthly and form a critical part of India’s drug quality transparency framework.
An NSQ classification means the medicine failed one or more quality parameters — this could include issues with dissolution (how the drug releases in the body), potency (active ingredient content), contamination, or labeling errors. In the most serious cases, a sample may be classified as “spurious” — meaning it is fake or deliberately adulterated.
📊 CDSCO’s Quality Surveillance: The Numbers in 2026
The CDSCO conducts routine quality testing throughout the year. Recent data from 2026 shows the scale of this monitoring effort:
- March 2026: 168 drug samples flagged as NSQ, as reported by ETV Bharat (April 2026)
- June 2026: 159 substandard drug samples flagged, with over 3,500 prosecution cases filed by CDSCO over the preceding five years, according to ETV Bharat (July 2026)
- June 2026 (additional): 111 batches — including common medicines like Paracetamol and Telmisartan — failed CDSCO quality tests, as reported by Medical Dialogues (June 2026)
- August 2026: 220 drug samples classified as NSQ, with one spurious drug sample detected in Delhi, as reported by The News Mill (September 2026)
- August 2026 (additional): 280 drug samples failed CDSCO quality tests, with one sample flagged as spurious, as reported by ETPharma (August 2026)
These figures demonstrate that the CDSCO’s quality surveillance is active and ongoing — but they also highlight why international buyers need to understand what these alerts mean and how to respond.
🏛️ How the CDSCO Monitoring System Works
The CDSCO’s drug quality monitoring operates through a multi-layered system:
- Market Sampling: Drug samples are randomly collected from pharmacies, retail outlets, and distribution channels across India’s states and union territories
- Laboratory Testing: Collected samples are sent to CDSCO’s regional laboratories and approved testing facilities, where they undergo analytical tests against Indian Pharmacopoeia (IP) standards
- NSQ Classification: Samples that fail any prescribed quality parameter are classified as NSQ and included in the monthly surveillance data
- Spurious Drug Detection: The most serious category — samples confirmed as spurious (fake/adulterated) trigger criminal investigation and prosecution
- State-Level Coordination: The CDSCO works with State Drug Regulatory Authorities (SDRAs), which are rated using the SHRESTH index launched in February 2026 to measure state-level regulatory performance
⚠️ Spurious vs. Substandard vs. NSQ: Know the Difference
Understanding the hierarchy of quality failures is essential for international buyers evaluating supplier risk:
- Not of Standard Quality (NSQ): The medicine contains the correct active ingredient but fails on a quality parameter — dissolution, potency, purity, or labeling. The product may still be therapeutically effective but does not meet regulatory specifications.
- Substandard: A broader category encompassing products that do not meet quality standards. This can include NSQ samples as well as those with manufacturing defects, expired shelf-life, or improper storage conditions.
- Spurious (Fake/Adulterated): The most severe classification. The product may contain no active ingredient, the wrong ingredient, or harmful substances. Spurious drugs are criminally prosecuted under the Drugs and Cosmetics Act, 1940.
🌍 What This Means for International Buyers
For buyers sourcing generic medicines from India, the NSQ data serves as a signal — not a reason to avoid Indian manufacturers entirely, but a reminder that due diligence matters. Here is how to use this information practically:
- Monitor CDSCO alerts regularly: The monthly NSQ data provides real-time visibility into quality issues. Buyers should track which therapeutic categories and manufacturers appear in these alerts
- Verify manufacturer history: Check whether a supplier’s products have appeared in NSQ alerts. A single historical mention is not disqualifying — patterns of repeated failures are a serious red flag
- Request quality documentation: Ask suppliers for Certificates of Analysis (CoA), WHO-GMP certificates, and CDSCO manufacturing license numbers. Cross-check these independently
- Understand the regulatory framework: India’s drug quality system has undergone significant reform in 2025-2026, including the enforcement of revised Schedule M (aligned with WHO-GMP) from January 2026 and the launch of the SHRESTH index for state regulator benchmarking
- Work with verified distributors: For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory
✅ Practical Checklist: Sourcing Indian Generics Safely
- ✅ Request the manufacturer’s CDSCO license number and verify it with the relevant State Drug Control authority
- ✅ Ask for a WHO-GMP certificate and confirm its validity period (WHO-GMP certificates are typically valid for 3 years with surveillance audits)
- ✅ Review the Certificate of Analysis (CoA) for each batch — ensure it covers identity, assay, dissolution, and impurity testing
- ✅ Check whether the product or manufacturer appears in recent CDSCO NSQ or spurious drug alerts
- ✅ Verify the Indian Pharmacopoeia (IP) monograph compliance — this is the prescribed quality standard for most Indian generics
- ✅ Confirm the manufacturer has not been subject to regulatory action, license suspension, or warning notices
- ✅ Ask about the manufacturer’s complaint and recall procedures — a robust quality system includes documented adverse event handling
- ✅ For larger purchases, consider commissioning independent third-party laboratory testing of samples before acceptance
- ✅ Keep records of all quality documentation — these are essential for customs clearance, regulatory compliance, and any future quality investigations
🔮 Recent Regulatory Developments
India’s drug quality infrastructure has seen significant changes in 2025-2026:
- Revised Schedule M (enforced January 2026): India’s GMP standard was revised to align more closely with WHO-GMP, with stricter requirements for manufacturing validation, quality control, and documentation
- SHRESTH Index (launched February 2026): The CDSCO introduced a performance index to rank State Drug Regulatory Authorities, creating accountability and benchmarking across India’s decentralized regulatory system
- GMP Audit Outsourcing: The CDSCO has moved toward outsourcing GMP inspections to the Quality Council of India (QCI) and has been building a cadre of over 1,500 trained experts to support the expanded inspection workload
- Digital Regulatory Platform: The DCGI has announced plans for an end-to-end digital drug regulatory platform, with the first phase expected within 18 months — aimed at streamlining approvals and improving transparency
💬 Final Thoughts
CDSCO’s NSQ alert system is a valuable transparency mechanism — it shows that India’s drug regulator is actively monitoring product quality and publishing the results. For international buyers, the key takeaway is not to be discouraged by the numbers, but to use them as part of a broader quality verification strategy. Indian generic medicines remain among the most affordable and widely trusted in the world, but like any sourcing decision, they require informed due diligence.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
For more information, contact IMSDA at contact@indiamedicine.org.